Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells

Lapatinib is an FDA-approved EGFR and HER2 tyrosine kinase inhibitor for the treatment of HER2-positive breast cancer patients. However, its therapeutic efficacy is limited by primary or acquired resistance. In the present study, we established breast cancers cells with acquired lapatinib resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Min, Huang, Wei, Liu, Rui, Kong, Yingli, Liu, Yang, Chen, Xiaole, Xu, Jianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287059/
https://www.ncbi.nlm.nih.gov/pubmed/34290605
http://dx.doi.org/10.3389/fphar.2021.651516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287059/
https://www.ncbi.nlm.nih.gov/pubmed/34290605
http://dx.doi.org/10.3389/fphar.2021.651516

Ejemplares similares